olema.com - חוב מצטבר של החברה OLMA

Olema Pharmaceuticals (OLMA) faces risks centered on the completion of final-stage trials and the drug launch, which puts pressure on liquidity. The company develops advanced oral inhibitors for targeted treatment in women's oncology. The market capitalization trend is fixed at 0.00. The business relies on external financing, as the drug development stage precludes the generation of current profits.

This indicator is calculated by summing short-term and long-term liabilities from the balance sheets. The metric measures the total credit load, determining the business's dependence on external financing and the risks of excessive leverage. For Olema Pharmaceuticals (OLMA), this reflects the cost of developing oncology drugs with support from Bayer. Effective expense management by leadership minimizes financial threats. By analyzing the dynamics of borrowed capital, an investor assesses the company's stability.